Overview

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

Status:
Completed
Trial end date:
2018-07-20
Target enrollment:
Participant gender:
Summary
A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Orpheris, Inc.
Treatments:
Acetylcysteine
N-monoacetylcystine